Literature DB >> 24793657

Porous silicon oxide-PLGA composite microspheres for sustained ocular delivery of daunorubicin.

Kaihui Nan1, Feiyan Ma2, Huiyuan Hou2, William R Freeman2, Michael J Sailor3, Lingyun Cheng4.   

Abstract

A water-soluble anthracycline antibiotic drug (daunorubicin, DNR) was loaded into oxidized porous silicon (pSiO2) microparticles and then encapsulated with a layer of polymer (poly lactide-co-glycolide, PLGA) to investigate their synergistic effects in control of DNR release. Similarly fabricated PLGA-DNR microspheres without pSiO2, and pSiO2 microparticles without PLGA were used as control particles. The composite microparticles synthesized by a solid-in-oil-in-water emulsion method have mean diameters of 52.33±16.37μm for PLGA-pSiO2_21/40-DNR and the mean diameter of 49.31±8.87μm for PLGA-pSiO2_6/20-DNR. The mean size, 26.00±8μm, of PLGA-DNR was significantly smaller, compared with the other two (P<0.0001). Optical microscopy revealed that PLGA-pSiO2-DNR microspheres contained multiple pSiO2 particles. In vitro release experiments determined that control PLGA-DNR microspheres completely released DNR within 38days and control pSiO2-DNR microparticles (with no PLGA coating) released DNR within 14days, while the PLGA-pSiO2-DNR microspheres released DNR for 74days. Temporal release profiles of DNR from PLGA-pSiO2 composite particles indicated that both PLGA and pSiO2 contribute to the sustained release of the payload. The PLGA-pSiO2 composite displayed a more constant rate of DNR release than the pSiO2 control formulation, and displayed a significantly slower release of DNR than either the PLGA or pSiO2 formulations. We conclude that this system may be useful in managing unwanted ocular proliferation when formulated with antiproliferation compounds such as DNR.
Copyright © 2014 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Daunorubicin; Ocular drug delivery; Poly(dl-lactide-co-glycolide); Porous silicon oxide

Mesh:

Substances:

Year:  2014        PMID: 24793657      PMCID: PMC4106702          DOI: 10.1016/j.actbio.2014.04.024

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  38 in total

1.  The effect of combined daunorubicin and triamcinolone acetonide treatment on a refined experimental model of proliferative vitreoretinopathy.

Authors:  E P Chen; U H Steinhorst; G P Samsa; P T Saloupis; D L Hatchell
Journal:  Invest Ophthalmol Vis Sci       Date:  1992-06       Impact factor: 4.799

2.  The effect of lauryl capping group on protein release and degradation of poly(D,L-lactic-co-glycolic acid) particles.

Authors:  N Samadi; A Abbadessa; A Di Stefano; C F van Nostrum; T Vermonden; S Rahimian; E A Teunissen; M J van Steenbergen; M Amidi; W E Hennink
Journal:  J Control Release       Date:  2013-06-07       Impact factor: 9.776

3.  Optimization of encapsulation of a synthetic long peptide in PLGA nanoparticles: low-burst release is crucial for efficient CD8(+) T cell activation.

Authors:  A L Silva; R A Rosalia; A Sazak; M G Carstens; F Ossendorp; J Oostendorp; W Jiskoot
Journal:  Eur J Pharm Biopharm       Date:  2012-11-29       Impact factor: 5.571

4.  Effect of WOW process parameters on morphology and burst release of FITC-dextran loaded PLGA microspheres.

Authors:  Shirui Mao; Jing Xu; Cuifang Cai; Oliver Germershaus; Andreas Schaper; Thomas Kissel
Journal:  Int J Pharm       Date:  2006-10-28       Impact factor: 5.875

5.  Real-time monitoring of sustained drug release using the optical properties of porous silicon photonic crystal particles.

Authors:  Elizabeth C Wu; Jennifer S Andrew; Lingyun Cheng; William R Freeman; Lindsey Pearson; Michael J Sailor
Journal:  Biomaterials       Date:  2010-11-30       Impact factor: 12.479

Review 6.  Recent advances in porous silicon technology for drug delivery.

Authors:  Timothy J Barnes; Karyn L Jarvis; Clive A Prestidge
Journal:  Ther Deliv       Date:  2013-07

7.  Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy.

Authors:  J A Khawly; P Saloupis; D L Hatchell; R Machemer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

8.  Efficacy of daunorubicin encapsulated in liposome for the treatment of proliferative vitreoretinopathy.

Authors:  Kohtaro Shinohara; Minoru Tanaka; Toshiro Sakuma; Yasuhiko Kobayashi
Journal:  Ophthalmic Surg Lasers Imaging       Date:  2003 Jul-Aug

9.  Controlled release carrier of BSA made by W/O/W emulsion method containing PLGA and hydroxyapatite.

Authors:  Mei Ling Ho; Yin Chih Fu; Gwo Jaw Wang; Hui Ting Chen; Je Ken Chang; Tsung Hsien Tsai; Chih Kuang Wang
Journal:  J Control Release       Date:  2008-03-04       Impact factor: 9.776

10.  Relationship between the solution thermodynamic properties of naproxen in organic solvents and its release profiles from PLGA microspheres.

Authors:  Diana Marcela Aragón; Jaiver Eduardo Rosas; Fleming Martínez
Journal:  J Microencapsul       Date:  2013-02-01       Impact factor: 3.142

View more
  5 in total

1.  Oriented Nanofibrous Polymer Scaffolds Containing Protein-Loaded Porous Silicon Generated by Spray Nebulization.

Authors:  Jonathan M Zuidema; Tushar Kumeria; Dokyoung Kim; Jinyoung Kang; Joanna Wang; Geoffrey Hollett; Xuan Zhang; David S Roberts; Nicole Chan; Cari Dowling; Elena Blanco-Suarez; Nicola J Allen; Mark H Tuszynski; Michael J Sailor
Journal:  Adv Mater       Date:  2018-01-24       Impact factor: 30.849

Review 2.  Biodegradable Microparticles for Regenerative Medicine: A State of the Art and Trends to Clinical Application.

Authors:  Anastasia A Sherstneva; Tatiana S Demina; Ana P F Monteiro; Tatiana A Akopova; Christian Grandfils; Ange B Ilangala
Journal:  Polymers (Basel)       Date:  2022-03-24       Impact factor: 4.329

3.  Insulin-loaded PLGA microspheres for glucose-responsive release.

Authors:  Jun-Zi Wu; Gareth R Williams; He-Yu Li; Dong-Xiu Wang; Shu-De Li; Li-Min Zhu
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

Review 4.  Bioerodable PLGA-Based Microparticles for Producing Sustained-Release Drug Formulations and Strategies for Improving Drug Loading.

Authors:  Felicity Y Han; Kristofer J Thurecht; Andrew K Whittaker; Maree T Smith
Journal:  Front Pharmacol       Date:  2016-06-28       Impact factor: 5.810

5.  Intravitreal safety profiles of sol-gel mesoporous silica microparticles and the degradation product (Si(OH)4).

Authors:  Yaoyao Sun; Kristyn Huffman; William R Freeman; Michael J Sailor; Lingyun Cheng
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.